{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:46Z","timestamp":1786998406874,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.yebeh.2016.02.023","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T23:30:27Z","timestamp":1460244627000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein"],"prefix":"10.1016","volume":"58","author":[{"given":"Scott","family":"Mintzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krunal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Chervoneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maromi","family":"Nei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.02.023_bb0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0010","first-page":"MT50","article-title":"The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy","volume":"10","author":"Nikolaos","year":"2004","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1528-1157.2003.44802.x","article-title":"Lipoprotein(a) concentration increases during treatment with carbamazepine","volume":"44","author":"Bramswig","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0020","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1528-1157.1994.tb01792.x","article-title":"Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine","volume":"35","author":"Isojarvi","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.21615","article-title":"Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein","volume":"65","author":"Mintzer","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2011.10.001","article-title":"Conversion from enzyme-inducing antiepileptic drugs to topiramate: Effects on lipids and c-reactive protein","volume":"98","author":"Mintzer","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/archneur.1993.00540060030012","article-title":"Serum lipid levels during carbamazepine medication. A prospective study","volume":"50","author":"Isojarvi","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0887-8994(98)00084-8","article-title":"Serum lipids and lipoproteins in patients treated with antiepileptic drugs","volume":"19","author":"Verrotti","year":"1998","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1440-1754.1997.tb01588.x","article-title":"Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants","volume":"33","author":"Verrotti","year":"1997","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(12)70105-9","article-title":"Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"11","author":"Baulac","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0060","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11745-002-1016-x","article-title":"The Role of Cytochrome P450 in the Regulation of Cholesterol Biosynthesis","volume":"37","author":"Gibbons","year":"2002","journal-title":"Lipids"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00280057","article-title":"Dose dependent enzyme induction by oxcarbazepine?","volume":"39","author":"Patsalos","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","article-title":"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0080","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1212\/WNL.45.6.1155","article-title":"Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy","volume":"45","author":"Eiris","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0085","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","article-title":"Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine\/Carbamazepine Monotherapy Trial Group","volume":"345","author":"Brodie","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ana.22229","article-title":"Antiepileptic drugs interact with folate and vitamin B12 serum levels","volume":"69","author":"Linnebank","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.wnl.0000310981.44676.de","article-title":"Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy","volume":"70","author":"Pack","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1528-1167.2006.00460.x","article-title":"Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine","volume":"47","author":"Mintzer","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MED.0b013e328345e533","article-title":"Hormonal consequences of epilepsy and its treatment in men","volume":"18","author":"Sivaraaman","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.02.023_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1528-1167.2012.03652.x","article-title":"Seizure recurrence and remission after switching antiepileptic drugs","volume":"54","author":"Wang","year":"2013","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T09:52:53Z","timestamp":1536832373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"alternative-id":["S1525505016000834"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.02.023","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}